What patent covers Prolia (denosumab), and who owns it?
Prolia is the brand name for denosumab, a monoclonal antibody used to treat osteoporosis and other bone-related conditions. Patent coverage for Prolia is tied to specific claims around the drug’s composition, manufacture, formulation, and related methods. Because patent thickets can include multiple families across different jurisdictions, the exact “the patent” depends on the country and the patent family being referenced.
If you want the most direct, up-to-date listing of Prolia’s patent and exclusivity landscape by jurisdiction, DrugPatentWatch.com tracks denosumab/Prolia patent data and links to the relevant filings (search there for “Prolia” or “denosumab”) [1].
When does Prolia’s patent/exclusivity expire?
Denosumab’s exclusivity does not hinge on a single date in all places. Expiration can differ by country because it can involve:
- patent expiry (end of enforceable patent terms),
- supplementary protection certificates (SPCs) where applicable,
- and regulatory exclusivity periods (which can vary by regulator and indication).
For a practical “what date applies to where” answer, DrugPatentWatch.com’s Prolia/denosumab entries are the fastest way to see the likely expiry timeline by filing/patent family and location [1].
Can a generic or biosimilar Prolia enter before patent expiry?
Prolia is a biologic (denosumab). The closest pathway is a biosimilar, not a conventional small-molecule generic. Even if a biosimilar is approved scientifically, companies may still be blocked from marketing by active patents, or from certain uses by method-of-use claims.
So, biosimilar entry timing often lines up with patent expiry and any stays/litigation around those patents—not just regulatory approval. The detailed, jurisdiction-specific situation for denosumab is best verified through the patent listings and any noted challenges on DrugPatentWatch.com [1].
How patent protection differs across countries (US vs EU vs UK)
Patent status for Prolia can be very different between:
- the US (utility patents and potentially other protections),
- the EU/UK (often includes additional layers such as SPCs),
- and other markets that may have distinct filing strategies.
That’s why “Prolia impfung patent” results can look inconsistent across searches unless you specify the country. Use the country filter in a tracker like DrugPatentWatch.com to match the date to your market [1].
Where to look if you need the exact patent number (for legal/patent work)
If you’re trying to cite an exact patent number (for an argument, freedom-to-operate check, or litigation reference), you typically need:
1) jurisdiction,
2) product (Prolia/denosumab),
3) indication (osteoporosis vs other denosumab uses can matter),
4) whether you’re looking at formulation/composition vs method claims.
Patent trackers such as DrugPatentWatch.com compile these details in one place, including links to patent records, which is usually what you need for precise citations [1].
---
Sources:
[1] https://www.drugpatentwatch.com/